Access to Comprehensive Genomic Profiling is limited due to missing funding and reimbursement

While important progress has been made in making genomic tests based on single biomarkers or a limited number of genes available to patients in Europe – access to CGP is much more limited.

This is due to the fact that current funding and reimbursement frameworks do not allow for routine testing for all relevant mutations.